Supplementary Material for: Lung adenocarcinoma size decrease after SARS-CoV-2 vaccination during long-term pembrolizumab treatment: A case report

A man in his late 40s was diagnosed with clinical stage IVB lung adenocarcinoma with a PD-L1 tumor proportion score of 100% and high tumor mutational burden. A partial response was achieved after administration of pembrolizumab. The patient received two doses of a SARS-CoV-2 vaccine (BNT162b2) after 59 courses, and a chest CT revealed consolidation in the peri-tumoral area, which subsequently disappeared, and the tumor continued to shrink in the next four months. This case provides indirect evidence for the persistence of cancer immunity during long-term treatment with immune checkpoint inhibitors and the potential for further activation.

一名年近50岁的男性被诊断为临床IVB期肺腺癌，其PD-L1肿瘤比例评分（PD-L1 Tumor Proportion Score）为100%，且肿瘤突变负荷（Tumor Mutational Burden）较高。患者接受帕博利珠单抗治疗后获得部分缓解。在完成59个疗程的治疗后，患者接种了2剂新型冠状病毒（SARS-CoV-2）疫苗（BNT162b2）；后续胸部CT检查显示肿瘤周围区域出现实变影，随后该实变影自行消退，且在后续4个月内肿瘤持续缩小。本病例为免疫检查点抑制剂（Immune Checkpoint Inhibitors）长期治疗期间癌症免疫持续存在以及免疫进一步激活的潜力提供了间接证据。